Curcumin Nano drug which can be considered as one of the most prominent achievements of the (Pre) Clinical Cancer Research Group has been welcomed by different Iranian media on Saturday May 5. Iran Nanotechnology Initiative Council and Vice-Presidency for Science and Technology have allocated specific news regarding this drug on their websites. Iranian Students' News Agency, Islamic Republic News Agency, Asre Rasaneh Newspaper, and Press TV were among those other media which have been reported related articles and web shows about this achievement of our group.

“This nanocarrier was made without the use of poisonous catalysts and has proven successful in clinical trials on a number of cancer patients,” said Dr. Ali Mohammad Alizadeh from the Tehran University of Medical Sciences and of course our principal investigator in PCCRG.

Research has proven that curcumin, which is found in turmeric, has anti-cancer and cancer preventing properties apart from its anti-oxidant and anti-inflammatory properties, he added.

When curcumin is prescribed in its edible form, it has a low effect on the targeted tissues because of its low absorption rate and fast metabolism which causes it to be flushed from the body, he noted.

However, by capsuling curcumin in nano-emulsions (nano curcumin) its medical properties increase, Alizadeh noted.
Even if prescribed in high dosages, the drug is proven not poisonous during first-stage clinical trials and is currently near the end of stage two clinical trials on drug-resistant breast and digestive tract cancers.

Alizadeh added that because all the basic materials required to manufacture nano-curcumin are available in the country it can be domestically mass-produced as an anti-cancer drug.

Results of the research have been published in BioMed Research International, vol. 2105, issue 824746, 2015, pp. 1-14.


Press TV
ISNA
IRNA